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Abstract
An IgG2 monoclonal antibody (mAb) solution was subjected to stirring, generating high 
concentrations of nanometer and subvisible particles, which were then successfully size enriched 
into different size bins by low speed centrifugation or a combination of gravitational 
sedimentation and Fluorescence-Activated Cell Sorting (FACS). The size-fractionated mAb 
particles were assessed for their ability to elicit the release of cytokines from a population of 
donor-derived human peripheral blood mononuclear cells (PBMC) at two phases of the immune 
response. Fractions enriched in nanometer-sized particles showed a lower response than those 
enriched in micron-sized particles in this assay. Particles of 5–10 μm in size displayed elevated 
cytokine release profiles compared to other size ranges. Stir-stressed mAb particles had 
amorphous morphology, contained protein with partially altered secondary structure, elevated 
surface hydrophobicity (compared to controls), and trace levels of elemental fluorine. FACS size-
enriched the mAb particle samples, yet did not notably alter the overall morphology or 
composition of particles as measured by Microflow imaging, Transmission Electron Microscopy, 
and Scanning Electron Microscopy-Energy Dispersive X-ray Spectroscopy. The utility and 
limitations of FACS for size separation of mAb particles and potential of in-vitro PBMC studies to 
rank order the immunogenic potential of various types of mAb particles is discussed.
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INTRODUCTION
The presence of aggregates in recombinant protein therapeutics is a serious concern due to 
their potential immunogenicity risk in patients.1–10 Some notable clinical examples of 
immunogenicity include Factor VIII7, human growth hormone (hGH),8 and most likely 
erythropoietin (EPO).2,3 Unfortunately, exactly how aggregates produce an immune 
response, and the extent of their impact in in-vivo responses, is not fully understood. 
Aggregates can arise at all steps of protein production: fermentation, expression, 
purification, formulation, filling, transport, storage, and administration.11,12 Since each 
protein has distinct physicochemical properties, it may aggregate differently depending on 
the environmental stresses and solution conditions, which in turn, may expose various 
epitopes that may be more immune reactive than others. For example, with monoclonal 
antibodies (mAbs), different solution conditions can lead to formation of different types and 
sizes of aggregates and particles.13–15 Various environmental stresses including interfaces, 
temperatures, freeze-thaw, containers, pH, ionic strength, excipients, and concentration can 
all lead to protein aggregation.16–22
Our knowledge of the immunogenic potential of protein therapeutics is confounded by the 
fact that in addition to the presence of aggregates, immunogenicity risk can be contributed 
by factors that may arise from many patient related factors such as genetics, age, disease-
related factors, and other concomitant medications the patient may be taking. The route of 
administration, dose, and the frequency of administration are also important factors. Product 
related factors such as non-human T-cell epitope content in sequence, origin of the active 
substance, process related contaminants, and formulation can impact immunogenicity as 
well. 23–26 The presence of so many variables complicates our understanding of the 
immunogenic potential of various therapeutic proteins. Therefore, determining the potential 
impact of aggregates by themselves on immunogenicity is very challenging. Despite these 
obstacles, a combination of in silico predictions 27–30, in vitro cell-based assays27,31–33, and 
in vivo transgenic animal models34–38 are currently being extensively evaluated to assess the 
relative potential of different protein aggregates and particles to elicit immune responses in 
humans.
One particularly promising in vitro approach is the use of human Peripheral Blood 
Mononuclear Cells (PBMC) derived from a healthy donor population with heterozygous 
MHC genotypes to screen antigens or mAb candidates for their propensity to stimulate 
certain features of the immune system.1 In-vitro models have been previously used to 
examine the immunogenicity of recombinant human erythropoietin-alpha39, recombinant 
Factor VIII39 and IgG mAbs40 with a certain degree of success. The correlation of clinical 
immunogenicity with the in vitro PBMC output was also investigated for an immunogenic 
human fusion protein. Subjects that induced IFN-gamma secreting T cells in PBMC were 
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associated with a higher magnitude of immune response (as detected by binding and 
neutralizing anti-drug antibody) in clinical trials.31 These in vitro assays are relatively 
cheaper and faster to perform than in vivo animal model-based studies, incorporate the 
diversity of the genetic polymorphism of alleles in the representative human population, can 
be used to screen a large number of candidate biotherapeutic mAbs during early 
development, and can be employed to compare the relative immunogenicity of different 
pharmaceuticals.27,31–33
Most of the studies to date have focused on evaluation of immune activation by challenging 
with heterogeneous sized aggregates. However, there is still a gap where the actual 
aggregate size associated with the immune size has not been thoroughly addressed. 
Previously, three different IgG mAbs, including the one used in this study, were stressed by 
a variety of different methods and the resulting particles were characterized in terms of size, 
particle counts, conformation, morphology, and reversibility.13,41 Different types of 
aggregates formed depending on the type of stress applied.13 These different stressed mAbs 
were tested in an in vitro system to compare their relative response in human PBMC.40 It 
was found that aggregates, prepared by stirring all three mAbs, displayed the highest 
response compared to aggregates generated by all the other stresses tested.40 These results 
indicated that the presence of a high number of 2-10 μm particles (which were partially 
reversible, and retained some folded structure) in the stir-induced sample may be responsible 
for the increased PBMC response.40
The purpose of this study was to further examine the impact of protein particle size on 
signature cytokine secretions of human PBMC at different stages of the immune response.40 
An IgG2 monoclonal antibody (mAb2) solution was stirred to generate protein particles of 
varying sizes. The mAb2 particles were then separated into various size enriched 
populations using (1) low speed centrifugation to enrich for nanometer vs. micron sized 
particles, and (2) Fluorescence Activated Cell Sorting (FACS) to separate enriched fractions 
of micron-sized protein particles. FACS is a promising approach for protein particle 
characterization, as was recently described by Rombach-Riegraf et al 42 for size separation, 
and for related applications such as to detect and differentiate subvisible protein particles 
from silicone oil protein particles. 43–4546 The stirring induced mAb particles were also 
physically characterized, before and after FACS separation, in terms of their particle 
number, size distribution, mass distribution, morphology and composition using a 
combination of techniques including Microflow imaging (MFI) with radar chart analysis, 
FTIR microscopy, and multiple electron microscopy analyses (TEM and SEM-EDS).
MATERIALS AND METHODS
Materials
The IgG2 mAb, subsequently referred to as mAb2, was supplied by Amgen Inc. at 10.1 
mg/mL. This mAb has been used previously to characterize the immune potential of 
different mAbs and their aggregates.40,47 The antibody was highly purified48 and endotoxin 
levels were confirmed to be in an acceptable range (< 1.00 EU/mL) for use in these cell 
based assays. The stock mAb2 solution was stored at 4 °C prior to use.
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Generation of Aggregates—The stock mAb2 was diluted to 1 mg/mL with 10 mM 
sodium acetate pH 5.0 (A5 buffer) and stressed by stirring (referred to as stir-20h) as 
described previously by Joubert et al.13 Stirring stress was chosen since previous work 
showed that stirring of this IgG mAb produced aggregates that induced the highest response 
from PBMC.40 Additionally, for biophysical comparison purposes, a 1 mg/mL solution of 
mAb2 was heated extensively at 90°C for 30 min (labeled heat control).
Size separation of mAb particles
Two techniques were used to enrich different size populations of stirring induced particles: 
(1) slow speed centrifugation, and (2) gravitational settling of the samples combined with 
Fluorescence Activated Cell Sorting (FACS), subsequently referred to as “FACS”. For 
method (1), 1 mL of stir-20h mAb2 sample was centrifuged at 2500 × g using a Baxter 
Hereaus Biofuge 15 Model 3604 (Deerfield, IL) for 5 min. The supernatant was removed 
and the pellet was resuspended in one mL of A5 buffer. For method (2), 5 mL of stir-20h 
mAb2 sample was gently pipetted into 12×75mm polypropylene tubes and allowed to settle 
in a disturbance-free environment for 3 h at room temperature. After 3 h, 200 uL aliquots 
were removed carefully from the top to the bottom using a pipetman with gel loading tips 
and collected into eppendorf tubes. The last aliquot in the tube (referred to as “bottom”) 
contained a greater number of larger micron-sized particles and this sample was then further 
size fractionated by FACS as described below.
Fluorescence Activated Cell Sorting (FACS)—A Beckman Coulter MoFlo XDP 
(Brea, CA) was set up as described in the instrumentation manual with calibrations done 
according to the manufacturer’s specifications. A flow cytometry size calibration kit from 
Invitrogen (Molecular Probes, Carlsbad, CA) was used for general size correlation between 
reference beads and protein particles. The bottom sample was filtered through a 70 μm nylon 
mesh filter into a 12 × 75 mm polypropylene tube, and then diluted 15–20x with A5 buffer 
(called “pre-sort”). Four polypropylene tubes, each containing 200 uL of A5 were placed at 
4°C in a sterile FACS sorting chamber. Samples were FACS sorted under the purify mode 
using a ceramic 70 μm nozzle tip at a pressure of 60 psi and at a speed of 5000–10,000 
events/sec. The gain and sensitivity values of the detectors were optimized to maximize the 
protein particle detection and threshold. The charge plates were set to 4000V. Intellisort I 
was used to determine drop delay using flow check fluorospheres. All experiments used 
phosphate buffered saline (PBS) at pH 7.2, as the sheath fluid, daily prepared using 
deionized water (Labconco, Kansas City, MO) under aseptic conditions. The sheath fluid 
passed through an inline 0.22 μm filter just prior to mixture with pre-sort. Endotoxin levels 
were tested in each part of the instrument and were found to be at an acceptable range after 
the rigorous cleaning procedure as described below. Summit software version 5.2 (Beckman 
Coulter) was used for data collection and data analysis was performed using Kaluza Flow 
Analysis (Beckman Coulter).
Endotoxin cleaning and testing
Removing Endotoxins—Prior to using the stir-stressed mAb samples in the in-vitro cell-
based assay, the samples were tested for endotoxin. High levels of endotoxin (>10 EU/mL) 
were present in the FACS-sorted samples despite sterilization of all instrument components 
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and use of aseptic procedures. Therefore a protocol was developed to remove endotoxins by 
washing the instrument and all of its components with various solutions in the following 
sequence: 1) 10% bleach for 2 hours 2) deionized (Labconco) water for 2 hours 3) 70% 
ethanol for 2 hours 4) deionized water for 2 hours, 5) 1% Triton-X 114 (Sigma, St. Louis, 
MO) for 2 hours, 6) deionized water for 3 hours 7) approximately 1 mg/mL polymyxin B 
sulfate solution (Sigma, St. Louis, MO) for 3 hours, and 8) final flushing with deionized 
water for 3 hours.
Endotoxin Testing—All protein samples and buffers were assessed for endotoxin levels 
by a LAL (Limulus amebocyte lysate) test with the Charles River Endosafe®-PTS™(Charles 
River, Wilmington, MA) system prior to being used in the biological assay. The analysis 
was performed according to the manufacturer’s instructions.
Particle counting and sizing of mAb particles
HIAC-Royco Liquid Particle Counter—HIAC/Royco liquid particle counter model 
9703 with a HRLD-150 sensor and PharmSpec software PharmSpec (HACH Ultra 
Analytics, Grants Pass, OR) was used for obtaining particle counts and size distribution in 
some experiments. The HIAC method is described in detail by Joubert et al.13,40
MicroFlow Imaging (MFI)—Particle images, size distribution, and counts were obtained 
using MFI System DPA4200 (Protein Simple, Santa Clara, CA). For analysis, stir-stressed 
mAb2 samples, generated at 1mg/mL, were diluted 100x in A5 buffer. Unstressed, buffer, 
and FACS sorted samples were diluted 25x prior to MFI analysis. After obtaining a clean 
base line, 300 μL of each sample was loaded using the peristaltic pump. No notable 
differences were observed in degassed versus non-treated samples (data not shown), so 
samples were not degassed for these studies.
MFI data analysis—Microflow imaging particle concentration data are displayed as either 
bar charts or radar charts, all corrected for dilution factors. Additionally, a plot of % 
Particles vs Sample (size bin) is displayed. The percentage of particles as detected by MFI 
was calculated by dividing the concentration of particles of a certain size range by the total 
number of particles in all size ranges. This percentage is referred to as “enrichment” 
throughout this manuscript. MFI morphology radar charts were generated in the size ranges 
2–5, 5–10, and >10 μm to evaluate changes in particle intensity and aspect ratios as 
described previously.15,49 Finally, MFI particle data were used to calculate the estimated 
mass of protein within the particles, in the following four size bins: 1–2, 2–5, and 5–10, 
>10μm, using the ellipsoid volume method recently described.50
Resonant Mass Measurement (RMM)—A Particle Metrology System (Affinity 
Biosensors, Santa Barbara, California) was used with a Hi-Q micro sensor to quantify 
submicron and small micron particles from 0.2 to 1.85 μm. Sensor calibration and reference 
solution preparations were done according to the manufacturer’s instructions. After a clean 
frequency trace was obtained, protein sample was loaded for 30 s, with a stop trigger of 200 
particles. This limit of detection was empirically determined and used throughout the study. 
A density value for mAb of 1.41 g/mL was used.
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Biological testing of mAb particles using PBMC (in vitro comparative immunogenicity 
assessment assay, IVCIA)
Isolating Peripheral Blood Mononuclear Cells (PBMC)—PBMC from healthy 
human donors were obtained from Amgen’s environmental health and safety department. 
PBMC were isolated according to the procedure described previously.40
Challenging PBMC with protein samples and controls—Peripheral blood 
mononuclear cells from up to eight human donors were plated and acclimatized in 96-well 
culture plates as described previously.40 Acclimatized cells were then challenged with 
control (unstressed), and stir-20h mAb2 samples at equal volume, equal protein 
concentration at 40 μg/ml (total protein in solution determined by OD280 measurements), or 
equal particle number (based on light obscuration or MFI measurements). Negative controls, 
consisting of buffers isolated by FACS or medium-treated cells, and positive controls, such 
as lipopolysaccharide (LPS) or phytohemagglutinin (PHA) were also tested. LPS and PHA 
were controls at the early or late-stage immune response, respectively. Samples were 
incubated for either 20 h or 7 days (in separate culture plates), to assess an early stage or late 
stage immune response, respectively, as described by Joubert et al.40
Meso-Scale Discovery Assay—A 96-well human cytokine electro-chemiluminescence 
assay kit K151AYB-1 (Meso-Scale Discovery, Gaithersburg, MD) was used, according to 
the manufacturer’s instructions, to quantify the concentration of monocyte chemotactic 
protein-1 (MCP-1) that was secreted by PBMC in response to the samples. The 96 well 
plates were analyzed using an MSD Sector Imager 6000 instrument (Meso Scale Discovery, 
Gaithersburg, MD) and MSD Discovery Workbench Software 4.0 (Meso Scale Discovery). 
SoftMax Pro was used for data analysis to convert the output luminescent units into protein 
concentration (pg/mL) using a standard curve. Responses were presented in terms of 
concentration of MCP-1 secreted and percentage of responding donors. To determine the 
percentage of responding donors, the stimulation index (SI) was also calculated. The SI was 
calculated by dividing the amount of cytokine detected (pg/mL) in the sample of interest by 
the cytokine detected in the unstressed sample. For these studies, a response was considered 
to be positive if the SI ≥ 2.0 (i.e., response of the PBMC to the stressed sample was at least 
two fold higher than the control). The percentage of donors (% donors) that responded was 
calculated by taking the total number of donors that had an SI ≥ 2.0 as a percentage of the 
total number of donors tested. The cutoff of SI ≥ 2.0 was determined by statistical analysis 
as described elsewhere.40
Multiplex Cytokine Analysis—Quantification of cytokines released from PBMC was 
performed using a multiplex plate format using Milliplex (EMD Millipore, Billerica, MA) 
human panel kits and a Luminex Multiplexing instrument (specifically a Luminex 
FLEXMAP 3D instrument from EMD Millipore) as described by Joubert et al.40 For 
analysis of the PBMC supernatants at the early phase (after 20h incubation), the following 
cytokines were monitored: IL-10, IL-1ra, IL-1α, IL-1β, IL-6, IL-8, MCP-1, MIP-1α, 
MIP-1β, TNF-α, and TNF-β. For analysis of the PBMC supernatants at the late phase (after 
7 days of incubation), the following cytokines were monitored: IFN-γ, IL-10, IL-12p40, 
IL-12p70, IL-13, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, and TNF-α. A robust PBMC response 
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was difficult to obtain due to the dilute nature of the FACS purified samples. Therefore, the 
concentration of cytokines released by the PBMC was directly reported and the percentage 
of responding donors was calculated differently than for the MSD results. The cytokine 
response was analyzed as follows: for each cytokine monitored, the number of donors, who 
responded the highest (by releasing the largest amount of that same cytokine) to a specific 
size-enriched particle-containing sample was determined. The number of donors that 
responded highest to this size bin was then taken as a percentage of the total number of 
donors that were tested. In all cases, negative controls such as buffer isolated by FACS and 
medium-treated cells showed minimal response and positive controls such as LPS and/or 
PHA showed a very high response (SI≫2.0; data not shown). In all cases, PBMC responses 
induced by the mAb samples were much lower than those induced by the LPS or PHA 
positive controls (data not shown).
Biophysical characterization of mAb particles
Extrinsic Fluorescence Spectroscopy—8-Anilino-1-naphthalene sulfonate (8,1-ANS) 
was used to study changes in the accessibility of apolar regions in the protein samples. An 
Agilent 8453 (Santa Clara, CA) was used with baseline and light scattering corrections.51 
Fluorescence data were obtained as described previously.15 A spectrum of buffer containing 
ANS was subtracted from each spectrum prior to data analysis using Microsoft Excel 
software. ANS peak positions and intensities were monitored and compared to that of the 
control samples to compare relative similarities or differences in surface hydrophobicity 
among samples.
Fourier Transform Infrared Spectroscopy/Microscopy—The control, heat, and 
stir-20h mAb2 samples in solution were analyzed with a Bruker Tensor 27 FTIR 
Spectrometer and Bio-ATR cell. Two hundred fifty-six scans were recorded from 600 to 
4000 cm−1 with a resolution of 4 cm−1 as described in detail in Telikepalli et al.15 For 
analyzing mAb particles in the bottom sample, 3 μm gold filters (Pall Corporation, Port 
Washington, NY) were used to capture and wash protein particles and then analyzed by 
FTIR microscopy as described in detail elsewhere.15
SDS-PAGE—Each sample other than the FACS sorted samples was dissolved in NuPAGE 
LDS sample buffer (Life Technologies, Carlsbad, California) with and without 50 mM 
dithiothreitol (BioRad Laboratories, Hercules, CA) and incubated at 90°C for 5 min. 
Approximately 3 μg of each sample was separated on a 3–8% Tris-acetate gel using Tris-
acetate running buffer (Life Technologies) for 65 min at 150V. A Hi-Mark unstained 
molecular weight ladder was used as a reference (Life Technologies). Protein bands were 
visualized by staining with Colloidal Coomassie (Invitrogen, Carlsbad, CA) according to the 
manufacturer’s instructions.
Transmission Electron Microscopy (TEM)—Six microliters of each sample was 
placed onto Lacey Carbon 300 Mesh Copper grids (Ted Pella, Redding, California) and 
allowed to sit for 2 min, with the excess wiped off by a Kimwipe. Stir-20h and bottom 
samples were diluted 100x with A5 buffer prior to being loaded onto the TEM grids. FACS 
sorted samples, heat-stressed, unstressed control, and buffers were loaded directly onto the 
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TEM grids with no dilution. The grids were then placed into filtered 2% uranyl acetate for 2 
min and extra stain was removed with a Kimwipe. The wet grids were air-dried for several 
min prior to being examined by TEM. Samples were imaged on an FEI Technai F20 XT 
Field Emission Transmission Electron Microscope (Hillsboro, OR) using 200 kV electron 
acceleration voltage. Images were captured at a standardized, normative electron dose and at 
a constant defocus value from the carbon-coated surfaces.52
Scanning Electron Microscopy (SEM)/Energy Dispersive X-ray Spectroscopy 
(EDS)—A FEI Versa 3D Dual Beam Scanning Electron Microscope/Focused Ion Beam 
(Hillsboro, OR) with an XMAX silicon drift detector (Oxford Instruments, Abingdon, 
Oxfordshire, UK) was used to obtain information regarding the surface morphology, 
elemental composition, and distribution of elements of the protein samples. SEM data was 
obtained at an acceleration voltage of 7 kV and a spot size of 4.0 using an Everthart 
Thornely (ET) detector for image collection. Elemental mapping and energy spectra were 
acquired and processed with AZtecEnergy software (Oxford Instruments, UK). For sample 
preparation, a small square piece of ruby red mica sheet (Electron Microscopy Sciences, 
Hatfield, PA) was mounted onto a standard SEM pin stub specimen mount (Ted Pella, 
Redding, CA). The grids prepared for TEM analysis were placed on top of the mica and a 
thin coating (3 nm) of electrically conductive material (gold) was deposited on the sample 
by a low vacuum sputter coater (Quorum Technology, Laughton, UK).
RESULTS
Initial comparisons of nanometer vs. micron sized mAb particles in a PBMC assay
As an initial experiment, the IgG2 mAb (mAb2) in 10 mM acetate buffer, pH 5 (A5 buffer) 
was stirred for 20h and the particles generated were fractionated by slow speed 
centrifugation to separate the supernatant and pellet, containing enriched nanometer and 
micron-sized particles, respectively. Figure 1 shows the size distribution of nanometer and 
micron-sized particles present in the supernatant and pellet components as measured by 
HIAC and resonant mass measurement (RMM). There was almost a 10-fold higher number 
of smaller nanometer-sized particles (0.2-1.5 μm) in the supernatant than in the pellet, which 
contained more of the micron-sized particles (2-150 μm). The percentage values shown in 
Figure 1 were calculated by dividing the number of particles in either the supernatant or 
pellet by the total number of particles present in both supernatant and pellet in a particular 
size range. Hence the percentages signify the enrichment of a given size range in the 
samples. For example, 83% of all the particles detected in the 0.2–1.5 μm range are in the 
supernatant, while only 17% of particles in this size range are in the pellet. In addition, 70% 
of the particles detected in the 2–10 μm range are in the pellet, but only 30% of the particles 
in this size range are in the supernatant. To get a better estimate for the precision of each 
technique, relative standard deviations (RSD) were calculated by testing the stir-stressed 
mAb2 multiple times (N=10) on RMM; the RSD over the size range 0.2 – 1.5 μm was about 
30%. Likewise, the RSD values from particle concentration measurements from HIAC were 
determined from multiple testing results from another mAb solution containing protein 
particles, which showed RSD values of 1% and 8% for the 2–10 μm particles, and for 
particles greater than 10 μm, respectively.53.
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The fractionated samples were then analyzed for their cytokine response using an in vitro 
comparative immunogenicity assessment (IVCIA) assay,40 as described in the Materials and 
Methods section. To accomplish this, we tested the propensity of the supernatant (enriched 
in nanometer sized particles) and the resuspended pellet (enriched in micron-sized particles) 
to elicit a response in PBMC by monitoring the level of MCP-1 secreted. MCP-1 was 
chosen as a representative cytokine since we previously identified this cytokine as part of 
the cytokine signature that is released by PBMC in response to aggregates at the early 
phase.40 PBMC from eight naïve healthy human donors were challenged with the mAb2 
stir-20h total, supernatant, and pellet samples; the secretion of MCP-1 was assessed at the 
early phase (20 h) by an electrochemiluminescence assay. These initial results are shown in 
Figure 2. The Y-axis on the left and corresponding colored bars represent the average 
concentration of MCP-1 detected in response to the different aggregated samples, while the 
Y-axis on the right and the corresponding gray bars show the percentage of donors that 
responded at least two fold higher to the aggregated samples above the unstressed mAb 
sample (SI ≥ 2.0). The dots represent the amount of cytokine secreted by each individual 
donor, and point out the distribution of responses across the population tested. Figure 2 
highlights the variability of MCP-1 expression levels for individual donors as well as the 
variability in responsiveness to the different mAb samples. Individual donors have an 
inherent level of responsiveness that is dependent on their immune status and baseline 
inflammatory state. It should be noted that the overall measure of immune responsiveness to 
a challenge was a cumulative output of both the concentration of the cytokine secreted 
(colored bars) and the percentage of donors that responded (gray bars).
The stir-20h total, supernatant, and pellet samples had different properties that might be 
important for causing a response in the assay, and so they were tested at equal volume, equal 
protein concentration and equal particle number in the assay, one at a time (Figure 2). When 
the three samples were challenged at equal sample volume, the stir-20h total sample (no 
fractionation) showed the highest response with respect to both the magnitude of secreted 
MCP-1 and the number of responding donors (Figure 2A). This sample also had the largest 
number of particles (it contained all the particles present in both the supernatant and pellet 
fractions before fractionation) so it was not surprising that it induced the largest response. 
The stir-20h pellet showed a higher response than the corresponding supernatant in terms of 
magnitude of cytokine secretion and number of responding donors. Similarly, at equal 
protein concentration (Figure 2B) and equal particle number (Figure 2C), the stir-20h pellet 
sample induced a higher response than the supernatant for both magnitude of cytokine 
secreted and the number of responding donors. At equal protein concentration, even though 
MCP-1 was detected when PBMC were challenged with the supernatant sample, none of the 
8 donors responded two fold higher than to the unstressed sample (Figure 2B). The 
percentage of responding donors is a particularly useful indicator of immune response since 
it is measured above the donor’s response to the unstressed mAb so it takes into account the 
inherent responsiveness of the individual. In all three cases (Figure 2A–C), the pellet sample 
induced a higher percentage of responding donors than the supernatant, regardless of 
whether the samples were tested at equal volume (38% vs 13%), equal protein concentration 
(38% vs 0%), or equal particle number (25% vs 13%), suggesting that micron sized particles 
enhance the response of PBMC in vitro to a greater extent than nanometer sized particles at 
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the early phase. The level of cytokine secretion induced by the mAb2 samples was, 
however, much lower than that induced by the positive control (lipopolysaccharide, LPS; 
data not shown).
To further test the wider applicability of these trends, the supernatant and pellet fractions of 
a second IgG2 monoclonal antibody were also tested in the IVCIA assay (data not shown). 
For both mAbs, the pellet fraction induced a higher response than the supernatant fraction, 
indicating that micron size particles induce a more robust response as compared to 
nanometer sized particles at the early phase.
Size enrichment of various micron sized particles using FACS
On the basis of the IVCIA data from evaluating stirring induced nanometer vs. micron sized 
mAb particles, it was observed that the larger micron sized particles showed higher relative 
responses in the donor population used (see above). We therefore set out to develop a 
method to size fractionate the micron sized mAb particles for further analysis. A wide 
variety (>20 conditions) of settling, centrifugation and filtration experiments were evaluated 
to size fractionate micron-sized, stirring-induced mAb2 particles with limited success (data 
not shown). After much trial and error experimentation, a methodology was identified that 
utilized a combination of gravitational settling under specific conditions combined with 
FACS, to enrich distinct micron sized particle populations (Figure 3A).
The stir-20h mAb2 sample was gravitationally sedimented for 3h under specific conditions 
(see Methods section). The bottom fraction (referred to as the “bottom” sample) was then 
collected. The particle concentration and enrichment factor of the bottom sample as 
measured by MFI, in comparison to the original stir stressed mAb2 sample, is shown in 
Figures 3B and 3C, respectively. The bottom sample was then passed through the FACS and 
the forward scattering area (FSC) vs. side scattering (SSC) area dot plots were obtained as 
shown in Figure 3D. Each dot represents a counted particle and the FSC signal is generally 
considered to be a good indicator of particle size.54 Based on some initial correlations 
between FACS gating schemes and MFI sizing data (data not shown), gating schemes were 
optimized for best size enrichment and are shown in Figure 3D as I, II, III, and IV. Based on 
these four gatings, the stir-20h bottom samples were sorted and collected. These four sorted 
samples (I, II, III, and IV) were collected and analyzed by MFI as shown in Figures 3E and 
3F. Sort 1 contains an enriched number of 1-2 μm particles, sort II contains an enriched 
number of 2-5 μm particles, Sort III an enriched number of 5–10 μm particles, and Sort IV 
an enriched number of greater than 10 μm particles (>10 μm); all sizes were calculated based 
on equivalent circular diameter (ECD). Comparing MFI enrichment results in Figure 3C 
with Figure 3F show a distinct enrichment in all four size ranges with good reproducibility 
as indicated by error bars. Comparing MFI counts in Figure 3B with Figure 3E, however, 
show a large decrease in particle concentration after FACS separation, due to an extensive 
dilution of the samples of over ~1000 fold. In this case, the FACS analysis had to be run 
numerous times (~20 runs over several months) to collect a sufficient volume of sample, for 
further analysis. Since so many runs were required for use in the PBMC assay, the FACS 
samples had to be collected and frozen after each run.
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For logistical reasons, FACS samples had to undergo a total of two freeze thaw (F/T) cycles 
prior to being evaluated in the IVCIA assay. The frozen FACS sorted samples from each 
individual FACS run were thawed, pooled with other similar sorts, aliquoted and frozen 
again. It was these pooled frozen samples that were then subsequently thawed for 
biophysical and FACS analysis. These FACS sorted samples contained predominantly 
subvisible particles in PBS buffer, since the mAb particles had been largely separated from 
free protein by the FACS. For example, total protein levels were below detection in these 
samples as measured by OD 280 nm measurements, SDS-PAGE, or with a colorimetric 
bicinchoninic acid (BCA) assay (data not shown). Therefore, protein levels within the 
subvisible mAb particles could only be estimated by calculation from MFI data.50 To 
initially characterize the size measurements with these samples, one of the FACS sorted 
samples that underwent two F/T cycles, was examined by MFI (N=9) to examine the 
precision of the MFI results with these FACS samples. RSD values between 20–25% were 
obtained for particle counts in the first three size bins (1–2, 2–5, and 5–10 μm), 60% for the 
largest size bin analyzed, and 20% for the total MFI particle counts (Figure 4A). These RSD 
values give the relative error associated with each of these particle counts in these different 
size ranges. Additionally, the FACS sort pools (Sort I, II, III, IV) that underwent 2 F/T 
cycles were directly analyzed by MFI (N=3). The particle enrichment factor for each of 
these four FACS samples is maintained after two F/T treatments (See results in Figure 3F 
vs. Figure 4B).
Table 1 summarizes subvisible particle number, size and mass characteristics, based on MFI 
analysis, for each of the pools of the four FACS sort samples (Sort I, II, III, and IV) that 
underwent two F/T cycles. The total particle concentration is shown including estimated 
ranges (based on twice the calculated RSD values from Figure 4). In addition, the particle 
concentration in each of the four size ranges (including enrichment values and estimated 
ranges) are shown. It is apparent here that the experimentally determined total particle 
concentration results (column 3) falls within the range expected based on RSD calculations 
(column 4) for nearly all of the FACS Sorts. In addition, the calculated mass of the protein 
particles in each size range, based on MFI morphology measurements and assumptions of 
protein particle density as described by Kalonia et al, 2014,50 is shown in Table 1.
IVCIA testing of FACS size-enriched populations of micron sized mAb particles
The four FACS samples described in Table 1 (Sort I, II, III, and IV) were next evaluated in 
the IVCIA assay. PBMC from 7 human donors were challenged with equal volumes and 
similar particle counts of each of these four FACS samples. The response to these FACS 
enriched micron-sized mAb particles was monitored at two different times, in the early stage 
(20 h incubation) and late stage (7 days incubation). Multiplex cytokine analysis was used to 
assess two different panels of cytokines that were specific for each stage of the incubation. 
The resulting cytokine profiles are shown in Figures 5 and 6. A head-to-head comparison of 
the PBMC response to Sort I (containing enriched 1–2 μm particles) and Sort III (containing 
enriched 5–10 μm particles) is shown in Figure 5 at both the early phase (20 h, Figures 5A, 
5B) and late phase (7 days, Figures 5C, 5D). Since the overall particle counts in each Sort 
sample were low, the PBMC responses observed were also low (compared to results shown 
in Figure 2).
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Comparison of results in Figures 5A with 5B show that the concentrations of cytokines 
released (colored bars corresponding to the left-hand Y-axis) by PBMC in response to Sort I 
vs. Sort III are similar. However, the percentage of donors that responded (shown on the 
right hand Y-axis) to Sort III is higher as compared to Sort I. Although this result shows that 
most of the donors responded more to the particles in Sort III than Sort I, it is important to 
keep in mind that this was not a dramatic response and the donors responded only 
marginally higher overall. Similar observations can be made by comparing results in Figures 
5C with 5D at the late phase of the PBMC response, which shows additional T-cell effector 
cytokines that are more specific to the late phase of the immune response. This subtle 
difference between Sort I and Sort III is thought to be partly due to the low particle counts, 
which prevented robust cytokine release. However, it is apparent that more donors 
consistently responded to the sort III sample than to the sort I sample.
Since Sort I showed a lower response than Sort III (Figure 5), it was not assessed further. 
Sorts II, III, and IV were further assessed (Figure 6). PBMC from 8 human donors were 
challenged with similar particle counts of Sort II, III, and IV and the resulting cytokine 
profiles are shown in Figure 6 at both the early phase (Figure 6A, 6B, 6C) and the late phase 
(Figure 6D, 6E, 6F). Lower numbers of particles were added to the PBMC culture for this 
comparison (as compared to Figure 5) as some of the sorts were more dilute and so less 
particles were added to keep the comparison equal among the Sort II, III and IV samples. 
Therefore, the overall response, in terms of cytokine concentration, was lower in Figure 6 as 
compared to Figure 5 probably due to the more dilute nature of the samples tested in Figure 
6. Despite these limitations, a trend of a greater number of responding donors across the 
different cytokines was observed for the sort III sample (enriched in 5–10 μm particles) for 
the PBMC at both the early and late phases of this in vitro assay (Fig. 6).
Biophysical characterization of FACS size-enriched populations of micron-sized mAb 
particles
The sort I–IV size enriched samples from the FACS contained subvisible particles, but an 
undetectable amount of free protein in solution (as detected by OD280, SDS-PAGE or BCA 
assay), so this provided an opportunity to characterize protein particles without the presence 
of IgG2 mAb in solution. Because these FACS samples had a low mAb particle 
concentration (and thus low protein concentration), only a limited number of physical assays 
could be used (see below). Therefore, the IgG2 mAb sample generated just prior to FACS 
separation was also characterized (stirring followed by gravitational settling and selection of 
the “bottom” sample) to better understand the nature of the micron-sized particles going into 
the FACS separation. These samples contained both protein particles and soluble IgG2 
mAb.
The biophysical analysis of the starting material for FACS analysis focused on four samples: 
two controls (unstressed and extensively heated mAb2 solutions as negative and positive 
controls, respectively), the stirred antibody solution (stir-20h), and the “bottom” sample 
from the stirred sample after gravitational settling (i.e., the starting material for the FACS 
separation). Only the heat-stressed control contained high molecular weight aggregates 
containing reducible covalent, disulfide linkages, which were not present in the other three 
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samples as measured by SDS-PAGE (Supplementary Fig S1). Figure 7 shows TEM, SEM, 
EDS, FTIR, and ANS fluorescence spectroscopy data for the four samples. The unstressed 
control (Figure 7; first row) contained few particles and thus could not be imaged by TEM 
and SEM-EDS (see Supplemental Figures S2 and S3). The unstressed mAb2 solution 
contains antibody with largely native secondary structure (intramolecular beta sheets) with 
characteristic positions of the two peaks at 1691 cm−1 and 1637 cm−1, as determined by 
second-derivative FTIR spectroscopy. It also shows virtually no extrinsic fluorescence 
intensity indicating limited exposure of apolar regions for ANS binding.
Similar biophysical analysis was then performed on the subvisible particle containing 
samples of mAb2. Results from heat stressed, stir-20h, and the bottom samples are shown in 
Rows 2, 3 and 4 of Figure 7, respectively. These particles were observed to be amorphous in 
nature by TEM and SEM and contained predominantly carbon, nitrogen, and oxygen by 
EDS analysis (as expected for protein). All protein samples contained trace levels of 
elemental chlorine, presumably bound to the mAb protein during exposure to NaCl solutions 
during purification. Interestingly, the stir-20h samples also contain fluorine, probably 
originating from the Teflon coated stir-bar, while the heated particles did not contain 
fluorine (unstressed and heat stressed samples also lacked fluorine; see Supplemental 
Figures S2 and S3). The heat control samples contained protein with structurally altered 
conformation, containing mAb with predominantly intermolecular beta sheets, as indicated 
by the 1621 cm−1 peak by FTIR, as well as increase in surface hydrophobicity relative to the 
unstressed control. The major peak in FTIR spectra of the particles isolated from the two 
stirred samples (stir-20h and bottom samples) was between the two control samples, even 
though there was some increased variability in peak position. The bottom sample showed 
the largest increase in ANS intensity indicating a relatively increased surface hydrophobicity 
(or aggregation) of protein within this sample (last row in Figure 7).
Thus, there is some level of structural alteration of the protein contained in the stir-induced 
protein particles as well as increase in surface hydrophobicity relative to the unstressed and 
heated controls. The bottom sample was the starting material for the FACS separation, 
leading to collection of Sorts I, II, III, and IV containing size enriched micron sized 
particles. The protein particles after FACS separation (Sorts I, II, III, and IV) were quite 
dilute compared to the samples described above, but were in sufficient number to be 
visualized by TEM and SEM (Figure 8). Representative TEM images at two resolutions 
(200 nm and 1 μm) with protein particles represented by the darker gray regions are shown, 
while the lighter, smoother, gray regions are due to the TEM grids used for sample 
preparation. Representative SEM images (5 μm resolution) are shown, and the protein 
particles appear lighter with unique shapes and are highlighted by the blue boxes. These 
SEM images provide a unique visual representation of the morphology of the protein 
particles compared to TEM. Aside from their size, the protein particles from the four FACS 
samples (Sorts I, II, III, IV) are similar morphologically. This is especially apparent in the 1 
and 5 μm resolution TEM and SEM images, respectively. The proteins within the blue boxes 
in the SEM images were analyzed for chemical composition by EDS (last column). Similar 
to the starting material used in the FACS separation, the FACS separated particles contain 
C, N, O, and trace amounts of chlorine and fluorine. Elemental mapping of these particles 
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confirmed that the fluorine was present only in the particles and not in the background or 
control samples (Supplemental Figure S4).
In addition, MFI data were used to compare the morphology of these purified particles by 
constructing radar charts.15,49,55 These radar charts are a data visualization technique, which 
facilitates comparisons of a specific morphological characteristic in a large number of 
samples such as their aspect ratio and transparency (intensity). The radar charts shown in 
Figure 9 focus on the morphological nature of the particles and do not display results on the 
concentration of particles in the different size bins (which are summarized in Table 1). For 
example, MFI morphology radar chart analysis of the Sort I, II, III, and IV FACS samples, 
and the bottom mAb2 sample (starting material for FACS separation) is shown in Figure 9. 
As shown in the key in Figure 9B, size bins start at 2–5 μm at the top of the circle and 
increase clockwise up to > 10 μm. The outermost circle has four more concentric circles 
within it and consists of a triangle, located in the center, pointing to three size bins. The 
triangle can get larger or smaller within the circle towards one or more size bin. Depending 
on whether the intensity parameter or aspect ratio parameter are being analyzed, the 
expanding triangle shows that the particles in that size bin are becoming elongated (aspect 
ratio; going from 1 to 0) or more opaque (intensity; going from 850 to 350 ILU).
To visualize whether a change occurred in a specific morphological parameter, the reader 
can compare the position of the triangle’s vertex across five concentric circles, which 
represent a measurement value of aspect ratio or intensity. Since each vertex of the triangle 
represents a different size bin, the expanding or contracting of each vertex towards the 
smallest to largest concentric circle, respectively, indicates that a change in a morphological 
parameter of particles within that size bin has occurred. From Figure 9A, no differences 
were observed in intensity or aspect ratio of FACS sorted mAb particles in the 2–5 μm size 
range although these small sizes approach the limit of MFI resolution for morphology 
parameters (around 4 μm). In the upper row of triangles in Figure 9, the vertex of the 
triangles pointing to 2–5 μm for all 5 triangles (corresponding to intensity parameter) are in 
the same position. This means that the transparency of the 2–5 μm particles present in each 
of these five samples is similar to one another. A similar observation can be made for the 
second row of radar charts (corresponding to the aspect ratio). There is no change in the 
aspect ratio of the 2–5 μm particles present in each of these samples. As a visual reference, 
the reader can use movement between the concentric circles to gauge changes in 
morphological parameters. For the 5–10 μm size bin, particles present in Sort I, III, and IV 
samples appear slightly more opaque than similarly sized particles in the bottom and Sort II 
samples. This can be seen in the upper panel of Figure 9A, where the triangle’s vertex 
corresponding to this size bin of the Sort I, III and IV radar charts are slightly more 
expanded towards the outermost concentric circle as compared to the similar vertex in the 
bottom and Sort II samples. Particles larger than 10 μm in the bottom and Sort II samples 
appear more opaque than similarly sized particles in Sort I, III, and IV. In terms of aspect 
ratio, the FACS sorted samples showed more elongated particles in the largest size bin 
(>10μm) compared to the bottom sample. Overall, Figure 9 helps determine that the 
morphological differences (aspect ratio and transparency, especially) arising from the FACS 
separation are relatively minor, and overall, the morphological parameters of the protein 
particles in the four FACS samples were similar.
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This work evaluated the immune activation potential of protein aggregates of varying size 
by examining size-enriched populations of stirring-induced mAb2 particles in an in-vitro 
cell based assay, known as IVCIA, with PBMC from human donors. As an initial set of 
experiments, we showed that micron sized protein particles enhanced cytokine secretion in 
the IVCIA assay to a greater extent than nanometer-sized particles. To determine which size 
subset of micron sized aggregates induced the greatest response, we utilized a combination 
of gravitational settling and FACS separation to obtain different micron size-enriched 
protein particles from a stirred solution of mAb2. FACS sorting resulted in isolated protein 
particles, with no detectable soluble protein in samples as measured by OD 280nm, SDS-
PAGE or BCA analysis, offering the opportunity for additional biophysical characterization 
of isolated protein particles (in addition to testing these particles in the IVCIA assay).
The mAb2 particles induced by stirring were shown, compared to untreated and heat 
stressed controls, to contain an amorphous morphology with protein within the particles 
having some structural alterations in their overall secondary structure and increased surface 
hydrophobicity, but retaining some of the native higher-order structures as well (Figure 7). 
The FACS separation results for these mAb2 particles are consistent with those of Nishi et 
al. in that this technique involves a relatively mild condition that does not disrupt particles to 
a detectable extent.45 In this work, even after two freeze-thaw cycles, significant size-
enrichment of mAb particles is maintained within the FACS sorted samples. This result 
indicates either these aggregates are irreversible, or that the conditions used to enrich and 
isolate them do not disrupt the reversible interactions. Previous characterization of 
aggregates of mAb2 generated by stirring demonstrated some reversibility upon dilution, 
supporting the second conclusion.40
Fluorescence-activated cell sorting separates particles by imparting a charge on the droplet 
containing them. From our analysis of morphology of the FACS sorted samples, although 
minor differences from MFI radar chart analysis were noted, it appears FACS does not 
dramatically alter the overall nature of particles before and after FACS separation. The small 
differences observed in the radar plots may actually reflect the different amounts of particles 
in different size bins (Table 1). Thus, when evaluating the average aspect ratio or intensity in 
a size bin, one also needs to consider the number of particles present in that bin. A 
combination of TEM, SEM-EDS and MFI analysis of the morphology and composition of 
mAb2 particles before and after FACS separation showed no notable differences (Figure 7, 
8, 9). Interestingly, particles generated by stirring contained fluorine as measured by SEM-
EDS, and this element was not present in the buffer and control mAb2 (unstressed and heat 
stressed) samples indicating that it was originating from the stir-stress (Teflon-coated stir 
bars were used in this study) and carried with the particles through the FACS separation. 
The presence of this element in protein particles and its impact on PBMC responses is a 
subject for investigation in future work. This result also highlights that generating particles 
under accelerated conditions (i.e., extensive stirring with a Teflon coated stir bar) does not 
necessarily mimic mAb particle formation under real-time storage conditions. In fact, 
fluorine was not observed in control or heat-stressed mAb2 samples.
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There are some practical limitations of the FACS technique for preparative isolation of 
protein particles that need to be improved in the future. First, FACS isolation results in 
significant dilution of the particle sample (~1000X in these studies) resulting in low particle 
yields (compare Figure 3B to Figure 3E). In fact, to prepare sufficient amounts of size-
enriched mAb particle samples for biophysical and biological testing in this work, many 
months of almost continuous FACS runs were required. This in turn required freezing of 
individual sorts from individual runs, followed by subsequent thawing, pooling and 
refreezing of particle preparations to obtain the Sorts I, II, III, and IV evaluated in this work. 
Even then, low particle counts obtained (< 10,000 particles/mL) approached the lower limit 
of particles required for the IVCIA assay and consequently led to low PBMC responses. In 
addition, it is also difficult to further concentrate the FACS separated particles without loss 
of material or inadvertently altering their size distribution due to additional processing. 
Although Rombach-Riegraf et al. showed that resorting IgG particle samples by FACS 
increases particle purity within distinct size bins42, this was not a viable option in our work 
since it would have dramatically decreased particle concentration even more, making the 
samples unsuitable for the in-vitro assay or biophysical characterization. Based on these 
considerations, further work is needed to develop a particle purification technique that can 
more effectively obtain sufficient quantities of highly concentrated size-enriched protein 
particle samples for use in these in-vitro assays.
The dilution from the FACS could result in the loss of reversible aggregates, so that the 
samples assessed after FACS analysis might be primarily irreversible aggregates. This 
should present a “worse case” for immunological potential assessment, but might not reflect 
the original aggregate population. It was found that even after two freeze-thaws, the FACS 
sorted samples retained a similar distribution of subvisible particle counts, indicating that 
they are in a fairly stable state where they do not appear to either dissociate or aggregate, 
indicating potential irreversibility. SDS-PAGE gels showed that the “bottom” sample, used 
as the starting material for FACS separation, did not contain covalently linked high 
molecular weight aggregates; unfortunately, due to the dilute nature of the FACS samples, 
they could not be assessed by this technique. It is possible that the bottom sample contained 
either covalently or non-covalently linked aggregates that dissociated upon sample 
preparation. In that case, the aggregates should be fairly reversible. However, more work 
needs to be done to further characterize the reversibility nature of these FACS sorted 
samples.
These IVCIA results are consistent with other studies that have examined the role of the size 
of subvisible particles in eliciting an immune response.35,40,56–63 For example, stressed 
conditions that generated high levels of subvisible particles elicited ADA titers in various 
mouse models with heat stressed allergens57, human growth hormone 58, and recombinant 
human interferon alpha 2b.35 Further evidence suggests that larger sized subvisible particles 
are more likely to elicit various immune responses. For example, when high pressure was 
applied to aggregates of human or murine growth hormone, subvisible particle counts 
declined along with a corresponding decrease in immunogenicity in mice. 58,64 These results 
agree with prior work using protein coated spheres as a model system for protein aggregates 
of different sizes where antibody-coated 5 μm microspheres induced a greater response in 
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(1) the IVCIA assay compared to heterogeneous stress-induced aggregate populations40, and 
(2) in a Xeno-het mouse model system compared to antibody-coated nanospheres (20–50 
nm).47 In this work, 5–10 μm sized protein particles displayed elevated levels of cytokine 
responses compared to the other sized mAb2 particles tested in the same IVCIA assay. In 
addition, the fraction enriched in high numbers of nanometer sized particles induced a lower 
response than the fraction enriched in micron sized particles in the IVCIA assay, indicating 
that nanometer sized particles may not be the preferred size range for inducing an immune 
response.
The role of structural integrity of protein molecules within particles on immune responses 
has also been widely studied. 35,40,56,57,59,61–63,65 Results from one of our laboratories have 
previously shown that aggregated solutions with high numbers of 2–10 μm particles and the 
retention of at least some folded protein structure caused the highest PBMC immune 
response.40 In another study, Filipe et al. subjected a fully human IgG1 to various stresses 
and found that the stress that formed the most micron sized particles, which were mostly 
native in structure, actually did not show a high immune response.59 Instead copper-
catalyzed aggregates, containing little to no visible and micron sized particles, low surface 
hydrophobicity, and large changes in secondary and tertiary structures were the ones that 
showed the highest ADA response in transgenic mice.59 This aggregate type was shown to 
contain a high level of copper and histidine oxidation,13,14 a modification not found in other 
types of stress treated aggregates. These results highlight the importance of aggregate type 
in inducing an immune response, which may be more important than size, amount, or 
morphology of the aggregates.59 In our work, the stirring induced mAb2 particles contained 
protein structural alterations in secondary and tertiary structure as shown by FTIR 
microscopy and extrinsic ANS fluorescence spectroscopy, respectively. Compared to the 
heat control, the stirred samples displayed some retention of native higher-order structures, 
which may be necessary for the observed PBMC response.
The inter-relationship of protein particle size, number and mass presents a challenge in 
determining the most important factors in generating an immune response. Rombach-
Riegraf et al showed that the mass of protein present in subvisible particles may be an 
important property.61 They saw a positive correlation between protein mass in subvisible 
particles, generated by stressing an IgG mAb, and the amount of antigen processed and 
presented by the dendritic cells (DC). The more subvisible particles there are, the greater the 
mass of protein, and consequently, the greater the presentation of peptide by DC, which can 
influence DC maturation and activation of CD4+ T cells61. While we did not design the 
IVCIA assay to examine the effect of protein mass of the FACS sorted samples, we 
subsequently estimated the weight of protein particles in Sorts I–IV using MFI morphology 
data using a new method from one of our laboratories.50 As shown in Table 1, Sort III, 
which showed the greatest response in the IVCIA assay, contained both the highest number 
of particles and the highest mass of protein present in the 5–10 μm size range (Table 1). 
Even then, roughly 25% of the total protein mass in this sample was estimated to be from 
the particles larger than 10 μm. Additionally, even though Sort IV contained a significant 
mass of protein calculated from the 5–10 μm particles, this sample showed a lower relative 
response in this PBMC in-vitro assay. Sort IV contained an enriched number of particles 
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greater than 10 μm, and consequently most of the mass of the protein was present in these 
particles. This highlights that both protein mass and number of particles are important 
factors for consideration in monitoring cytokine responses in this assay.
In summary, we observed that size-enriched fractions of stirring-induced mAb2 particles, 
especially in the 5–10 μm range, elicited a relatively greater cytokine response in a number 
of PBMC donors in the in-vitro assay. However, many questions remain. In terms of 
physical characteristics of the mAb aggregates, it would be beneficial to use the methods 
established in this work to perform additional case studies with FACS size-enriched mAb 
particle populations (e.g., with different mAbs and different stresses and thus different 
physicochemical characteristics) to determine if the trends in size and immune potential 
observed in this work are generally observed across different types of mAb aggregates. In 
terms of biological readouts, even though this PBMC in-vitro model avoids the challenges 
associated with animal models, accounts for human genetic diversity, and mimics 
administration of the drug, it still requires a large number of particles, perhaps much more 
than clinically relevant, to obtain a strong signal.40 Additionally, it is important to note that 
the cytokines monitored in this study serve as biomarkers of early and late phases of the 
immune response in this in-vitro system. They are useful tools to assess the relative response 
of a diverse human population of PBMC and to rank responses relative to different types of 
aggregates. However, how the PBMC cytokine responses correlate with various in-vivo 
immune processes or immunogenicity is currently unknown due to the complexities arising 
from the pleiotropic nature of cytokines and the complexity of the immune system where the 
T cell driven B cell response and consequent signaling and antibody formation cannot be 
reproduced in-vitro. A combination of this in-vitro assay with other in-silico and in-vivo 
models, however, should result in enhanced predictive value in determining the relative 
immunogenic potential of different therapeutics.
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Separation of nanometer-sized vs. micron-sized stirring-induced particles of mAb2 by low 
speed centrifugation. A) Schematic of experimental setup, and B) particle number and size 
distributions of the fractionated samples are shown in three different size ranges. The 
concentration of smaller particles (0.2–1.5 μm) for both supernatant and pellet was obtained 
by Resonant Mass Measurement (RMM; estimated RSD ~30 %, see text). The concentration 
of particles 2 μm to greater than 10 μm was obtained from light obscuration measurements 
(HIAC; estimated RSD 1%-8%, see text). The percentages were calculated by dividing the 
number of particles in either the supernatant or pellet by the total number of particles present 
in both supernatant and pellet at a particular size range.
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Peripheral blood mononuclear cells (PBMC) from 8 human donors were incubated with 
solutions of mAb2 particles (see Figure 1) and examined for the release of MCP-1. MCP-1 
was measured by electro-chemiluminescence at the early phase (20 h incubation) at (A) 
equal sample volume, (B) equal protein concentration, and (C) equal particle numbers. The 
average concentration (n=8, colored bars) of MCP-1 and percentage of donors that 
responded (gray bars) to the aggregated mAb (two fold above the unstressed mAb2) is 
shown. The black dots represent the concentration of MCP-1 secreted by each individual 
donor. Different aggregate samples are shown horizontally as follows; stir-20h total (white), 
stir-20h supernatant (enriched in nanometer size particles; light blue), and stir-20h pellet 
(enriched in micron sized particles; orange); see Figure 1. The media and buffer-stressed 
controls responded far below the threshold, and the LPS positive control responded much 
more intensely (SI≫2.0) than the aggregated protein.
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Enrichment of different micron sized mAb2 particle populations using FACS separation. (A) 
Flowchart of experimental steps. (B) Subvisible particle counts in stirred sample (stir-20h) 
and bottom fraction after gravitational settling (bottom sample) as measured by MFI. (C) 
The percentage of particles in each size bin for these same two samples. (D) Upon FACS 
sorting the bottom sample, a two dimensional dot plot of response from forward vs side 
scattering signals (FSC Area vs. SSC Area) is generated with gatings labeled Sort I–IV, (E) 
Sorts I–IV were analyzed for subvisible particle distribution with MFI. (F) The percentage 
of particles in each size bin were determined. The graphs represent the average of three 
separate experiments (N=3) with the error bars representing one standard deviation.
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Determination of relative standard deviation percentage (RSD %) of MFI particle count and 
determination of enrichment factors for FACS separated samples of mAb2 particles. (A) 
Representative FACS sorted sample of stir-induced aggregated mAb2, obtained as outlined 
in Figure 3 and having undergone two freeze-thaw cycles, was used for repeat MFI testing 
to determine RSD % as a function of particle size bins (N=9 with the error bars representing 
one standard deviation), and (B) enrichment analysis of FACS sorted samples (Sort I, II, III, 
IV) after undergoing two freeze-thaw cycles. Data are an average of three separate 
experiments (N=3) with the error bars representing one standard deviation.
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Peripheral blood mononuclear cells (PBMC) from 7 human donors were incubated with 
mAb2 particle samples collected from the FACS separation and analyzed for cytokine 
release. Sort I (containing enriched 1–2 μm particles) (A, C) and Sort III (containing 
enriched 5–10 μm particles) (B, D) from FACS separation as well as the relevant controls 
were tested for the release of cytokines by multiplex cytokine analysis at the early phase (20 
h) (A, B) and late phase (7 day) (C, D). FACS samples were added to the PBMC culture at 
equal volume and similar particle concentration (high concentration; > 20,000+ particles/mL 
in culture). The average concentration across donors (N=7, colored bars) of the 11 cytokines 
tested at the early phase (A, B) and 12 cytokines tested at the late phase (C, D) is shown. 
The percentage of responding donors (gray bars) represents the number of the 7 donors 
tested that responded higher (by magnitude of secreted cytokine) to each sort. The black dots 
represent the concentration of cytokines secreted by each individual donor. The LPS-and 
PHA-positive controls responded much more intensely (SI≫2.0) than the aggregated 
protein samples (data not shown).
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Peripheral blood mononuclear cells (PBMC) from 8 human donors were incubated with 
FACS isolated mAb2 particle samples (containing very little soluble aggregates): sort II 
(enriched in 2–5 μm particles) (A, D), sort III (enriched for 5–10 μm particles) (B, E), and 
sort IV (enriched for particles > 10 μm) (C, F) and analyzed for their cytokine release. The 
FACS samples were added to the PBMC culture at similar particle numbers (low 
concentration; >9,000+ particles/mL in culture). These FACS samples as well as the 
relevant controls were tested for the release of signature cytokines by multiplex cytokine 
analysis at the early phase (20h) and late phase (7 days). The average concentration across 
donors (N=8, colored bars) of representative cytokines tested at the early and at the late 
phases is shown. The percentage of responding donors (gray bars) represents the number of 
the 8 donors tested that responded higher (by magnitude of secreted cytokines) to each sort. 
The black dots represent the concentration of cytokines secreted by each individual donor.
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Biophysical analysis of mAb2 solutions containing stirring-induced particles that were used 
as starting material for FACS separation. Control samples (unstressed and heat denatured) 
and two stirred samples (Stir-20h, Bottom) of mAb2 were characterized for morphology by 
SEM and TEM, composition by EDS, overall secondary structure by solution FTIR and 
FTIR microscopy, and surface hydrophobicity by extrinsic fluorescence using 1,8-ANS as 
indicated in this Figure. Representative TEM and SEM images are shown at two resolutions 
(the unstressed control had virtually no particles so no TEM and SEM images are shown). 
For FTIR analysis, shifts in two peaks for intramolecular beta sheet content (occurring 
between 1620 to 1640 cm−1 and 1690 to 1700 cm−1) were monitored in the second 
derivative FTIR spectra. The peak minima are shown for each sample (N=3 with the error 
bars representing one standard deviation).
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Representative TEM (200 nm and 1 μm resolution) and SEM (5 μm resolution) images of 
mAb2 particles of four different FACS sorted samples (Sort I, II, III, IV). The SEM particle 
images (representative graphs shown here), selected by the blue boxes, were also analyzed 
for their elemental composition by EDS as shown in far right column of the figure.
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Radar plots of MFI morphology data (aspect ratio and intensity; refer to the key in B) for 
subvisible particles of mAb2 present in the starting material for FACS (bottom sample) and 
FACS sorted samples (sorts I-IV, see text) are shown in A. Radar plots show MFI 
morphology data distributions of the micron sized particles that fall within each of the three 
size bins shown in the key of B. The data shown are the average of three separate 
experiments (N = 3) and the error represents one standard deviation.
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